Backed by Big Pharma VCs, Palleon ramps up a new approach to immuno-oncology with a $48M startup round
A couple of years ago, GSK’s venture arm SR One brought in Jim Broderick as its first-ever entrepreneur-in-residence. And today, they’re backing his new cancer R&D play, helping bankroll a $47.6 million startup round for his upstart biotech Palleon.
These past two years have included an education in the converging roles of glycoscience and human immunology, Broderick tells me. Starting with observations on the varying role of glycans in either activating or braking the immune system, his search involved bringing together some of the top scientists in the field.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.